Hospitals and commercial companies are testing thousands of patients for COVID-19 daily, but face reagent and supply shortages.

Manufacturing sites are ramping up production of reagents needed to isolate SARS-CoV-2’s genetic material—a key step in testing for the virus.

Two papers reveal that many commonly used research antibodies don’t bind as believed, highlighting the need to validate these reagents before use.

Researchers have flagged several issues with so-called SmartFlares over the years, and it’s still unclear why they don’t appear to work under certain circumstances.

This guide for apps comes from personal experience testing various programs aimed to improve productivity or to help with selecting reagents.

With many probes being seriously flawed, Probe Miner helps researchers find those that are most specific and effective for manipulating their chosen proteins.

Leonard Freedman, president of the Global Biological Standards Institute, discusses the causes of irreproducible science and his latest effort to spread best practices.

A heat block, a truck battery, and a novel RNA amplification assay make for in-the-field surveillance of the virus.

A startup aims to make doing research easier by mining publications for research products, protocols, and potential collaborators.

Facing problems of inconsistent, time-consuming, and costly antibody production, some researchers are turning to alternatives to target specific proteins of interest, in the lab and in the clinic.

A survey of The Scientist readers identifies product trends and developments in life science reagents and kits.

Two giants merge as the German drug maker acquires the US-based science supply company.

Quantitative real-time technology dominates the market today but digital PCR is on the rise.

Biological resource centers are bigger and better than ever before, storing and distributing shared reagents, plasmids, and more.